Lord’s Mark secures UK MHRA registration for IVD portfolio

Lord’s Mark Industries has secured UK MHRA registration for its in-vitro diagnostics portfolio, enabling commercial sales in Great Britain from December 2026, two months ahead of schedule. The approval covers analysers, diluents and cleaning agents, strengthening the company’s healthcare expansion alongside its Renalyx dialysis system and planned pathology laboratory launch in January 2027.